Enzyme assay for mutant firefly luciferase

ABSTRACT

Enzymes and methods suitable for assaying ATP, and specific application for such assays are described and claimed. In particular, there is described a recombinant mutant luciferase having a mutation for example, in the amino-acid corresponding to amino acid residue number 245 in  Photinus pyralis,  is such that the K m  for ATP of the luciferase is increased e.g. five-fold with respect to that of the corresponding non-mutated enzyme such that it is of the order of 500 μm-1 mM. Also disclosed are luciferases having additional mutations conferring improved thermostability or altered wavelength of emitted light. Recombinant polynucleotides, vectors and host cells are also disclosed, as are methods of assaying the amount of ATP in a material (e.g. cells) optionally in real-time. Also disclosed are test-kits for in vitro assays.

TECHNICAL FIELD

The present invention relates broadly to enzymes and methods suitablefor assaying ATP. It further relates to specific applications for suchassays.

BACKGROUND ART

Intracellular ATP concentrations can vary 10-fold or more depending upona cell's state of health or developmental stage. It is of great value tobe able to measure fluctuations in intracellular ATP levels as a meansof investigating e.g. the effects of drugs, toxins, hormones,environmental agents or disease on cells.

There is apparently at present no convenient method for analysing theconcentration of ATP in vivo. For instance, in Dementieva et al (1996)Biochemistry (Moscow) Vol 61, No. 7., the intracellular concentration ofATP was measured in E. coli by calculating the total amount of ATPpresent using a recombinant luciferase, and dividing by an estimatedtotal cell volume.

Such an indirect approach can at best produce only an estimate of theactual ATP concentration.

The measurement of ATP concentration in cells has also been performedusing an in vitro coupled assay, such as that disclosed in the SigmaDiagnostic Kit Catalog No. 366, in which Phosphoglycerate kinase is usedto convert 3-phosphoglycerate to 1,3 diphosphoglycerate in an[ATP]-dependent fashion. The 1,3 diphosphoglycerate is then converted toglyceraldehyde-3-P concommitantly with conversion of NADH to NAD, whichcan be monitored spectroscopically. The assay has a dynamic range up to1 mM; the expected range is 380-620 μm when used with blood cells.

However it can be seen that, as with all coupled assays, the test isinevitably cumbersome to perform. Additionally it could not readily beadapted for in vivo use. It would thus be a contribution to the art toprovide materials and methods which overcome some of the drawbacks ofthe prior art.

DISCLOSURE OF THE INVENTION

In a first aspect of the invention there is provided a recombinantmutant luciferase having a mutation which is such that the K_(m) for ATPof the luciferase is increased with respect to that of the correspondingnon-mutated enzyme. Preferably the K_(m) is at least double that of thenon-mutated enzyme, and more preferably at least around five, ten, ortwenty times higher than that of the non-mutated enzyme.

Luciferases are, of course, already known in the art. In the presence ofMg²⁺, luciferase (originally obtained from fireflies) catalyzes thereaction of luciferin, ATP and O₂ to form oxyluciferin, AMP, CO₂,pyrophosphate and light. This basic property (luciferin and ATP toproduce light) is hereinafter referred to as ‘luciferase activity’.

The term ‘luciferase’ as used in relation to the invention is intendedto embrace all luciferases, or recombinant enzymes derived fromluciferases which have luciferase activity. This explicitly includesrecombinant mutant luciferases which have deletions, additions orsubstitutions to their amino acid structure provided that they retainluciferase activity. Such luciferases will typically have considerablehomology (e.g. up to 70, 80, 90, or 99%) with wild-type enzymes. Howeverthe crucial technical feature of the luciferases of the presentinvention which distinguishes them from those of the prior art is thatthey have a mutation which causes an increase in the K_(m) for ATP ofthe luciferase as compared with that measured for a corresponding enzymewhich differs only in it that it lacks that same mutation.

This increase K_(m) may be measured by the person of ordinary skill inthe art by conventional enzyme assays, as described in more detail inthe Examples below.

It should be noted that in the prior art, luciferase has sometimes beenused as a marker for gene expression (in vivo) where its production in acell is linked to a particular genetic control element. Luciferin isadded exogenously and intracellular ATP concentrations, under almost allconditions, will be such that the enzyme is saturated. Thus theswitching on of gene expression is signalled by light that is emitted ina quantitative manner according to the amount of active luciferase thatis generated.

However it should be stressed that in the previously known systems it isgenerally the concentration of luciferase which is measured; thisconcentration is then correlated with a different event e.g. theefficiency of a promoter. Indeed it has, on occasions, been an object ofthe prior art teaching on luciferases to reduce the K_(m) for ATP seee.g. WO 96/22376) which ensures that changes in the ambient [ATP] doesnot interfere with the assay.

Similarly the assay disclosed by Dementieva et al (1996) discussed aboverequires that all of the ATP be efficiently converted to light so thatthe total ATP present can be calculated. This approach requires a lowK_(m) luciferase so that the enzyme operates at near maximal velocityuntil all the ATP is hydrolysed.

By making available luciferases which have an increased K_(m) comparedwith those already known in the art, the present inventors have for thefirst time opened up the possibility of using these enzymes to measuresteady state ATP concentrations over range which was previouslyunsuitable. This is because, generally speaking, the relationshipbetween enzyme velocity (V, as measured by light intensity) andsubstrate concentration (of ATP, where luciferin is in excess) is asfollows:

 V=V _(m.)[ATP]/K _(m)+[ATP]

It can therefore be seen that only when the K_(m) is greater than (or ofa similar order as) the ambient [ATP] will there be a degree ofproportionality between changes in [ATP] and changes in light intensity.Where the K_(m) is much less than the ambient [ATP], any changes in[ATP] will not tangibly effect the measured light intensity. Clearly themore sensitive the light detection is, the smaller the measurablechanges in ‘V’ can be, and the smaller the K_(m) can be with respect tothe [ATP] range being assessed.

For certain applications, e.g. in vivo measurements, it may beadvantageous to have a luciferase wherein the K_(m) is of the order ofbetween 400 μm to 1.4 mM e.g. 500 μm, 600 μm, 1 mM etc. However, as canbe appreciated from the discussion above, the main criterion is that theK_(m) is not much less than the expected [ATP] range to be assessed, andthe phrase ‘of the order of’ should be construed accordingly.

A particular expected [ATP] range which is important for physiologicalassays of blood cells is between 300 μm and 1 mM, or more particularly380 μm and 620 μm, (cf. Sigma Diagnostic Kit, Catalog No. 366 discussedabove). For other mammalian cells such as hepatocytes, the [ATP] rangeis 2.5 mM-6 mM (see Dementieva et al (1996) discussed above. Use of therecombinant luciferases of the present invention for continuous assaysin these ranges is particularly envisaged.

The disclosure of the present application makes such high K_(m)luciferases available for the first time. The prior art disclosuresreveal only luciferases having a K_(m) of between 60 μm and 150 μm,which would be saturated in these ranges.

It is also advantageous, as with all enzymes used in assays, that themutant enzyme retains sufficient activity (i.e. a high maximum turnovernumber, giving a high V_(m)) such that practical concentrations ofenzyme can give detectable results.

Preferably the activity for ATP of the mutant is at least 5-100% of thatof the corresponding wild-type; however reduced-activity as a result ofthe high K_(m) mutation can, if necessary, be compensated for by usingmore enzyme or more sensitive detection if required.

In one embodiment of the first aspect there is disclosed a luciferasewherein the amino-acid corresponding to amino acid residue number 245 inPhotinus pyralis has been substituted with respect to the correspondingwild-type amino acid residue such that the K_(m) for ATP is increasedwith respect to that of the corresponding non-mutated enzyme.

It should be noted that the sequences of a number of luciferases fromdifferent sources have already been published in the literature see e.g.WO 95/25798 for P pyralis (SEQ ID NOs:1, and 21); EP 0 524 448 forLuciola cruciata (SEQ ID NOs:13 and 14) and Luciola lateralis (SEQ IDNOs:15 and 16). Other known luc genes include Luciola mingrelica (SEQ IDNOs:17 and 18), and Lampyris noctiluca (SEQ ID NOs:19 and 20) (see Newbyet al (1996) Biochemical J 313: 761-767.)

Whether an amino-acid in a luciferase ‘corresponds’ to number 245 in Ppyralis (which is His in the wild-type, non-mutated enzyme) can beestablished by the person of ordinary skill in the art withoutdifficulty as follows: the sequence of the luciferase is established(either from the literature or by sequencing); the sequence is alignedwith P pyralis, for instance using commercially available software (e.g.“Bestfit” from the University of Wisconsin Genetics Computer Group; seeDevereux et al (1984) Nucleic Acid Research 12: 387-395) or manuallysuch as to demonstrate maximal homology and align conserved amino acids;the amino acid corresponding to number 245 in P pyralis is identified.An example of this is shown below using L cruciata—the correspondingacid in that case is number 247.

Once identified a mutant can be prepared e.g. by site directedmutagenesis by methods commonly used in the art and exemplified below.

Preferably corresponding amino-acid is substituted for an unchargedamino acid, for instance nonpolar (e.g. Ala) or uncharged polar (e.g.Asn, or Gln):

CLASS EXAMPLES OF AMINO ACID Nonpolar: Ala, Val, Leu, Ile, Pro, Met,Phe, Trp Uncharged polar: Gly, Ser, Thr, Cys, Tyr, Asn, Gln Acidic: Asp,Glu Basic: Lys, Arg, His

It should be noted that WO 95/18853 (PROMEGA) lists a large number (over80) of Pyrophorus plagiophtalamus mutants which are reported to havealtered spectral properties. However the K_(m) for ATP of the mutants isnot reported, nor indeed discussed at any point in the application.

In another embodiment of the first aspect there is disclosed aluciferase wherein the amino-acid corresponding to amino acid residuenumber 318 in Photinus pyralis has been substituted with respect to thecorresponding wild-type amino acid residue such that the K_(m) for ATPis increased with respect to that of the corresponding non-mutatedenzyme. Correspondence may be assessed as above; preferably the aminoacid (Ser in the wild type) is substituted for a bulkier one (e.g. Thr).

In preferred forms the mutant luciferases of the present inventionincorporate one or more further mutations capable of conferring one ormore of the following properties with respect to a correspondingnon-mutated enzyme: improved thermostability; altered wavelength ofemitted light. Some suitable mutations are already known to thoseskilled in the art; see e.g. WO 95/25798 and WO 96/22376 and EP 0 524448 for thermostability improving mutations (e.g. at positionscorresponding to 354 and 215 of P pyralis).

Preferably the mutation causing the increased K_(m) itself improves oneor more of these properties, particularly thermostability. It should benoted that an enhanced stability at around 37° C. is especiallyadvantageous for enzymes which are to be employed in vivo.

In a further embodiment the luciferases may be in the form of fusionproteins or incorporate polypeptide extensions. This may improve theease by which they can be produced, localised in vivo or extracted andpurified.

In a second aspect of the invention there is disclosed a recombinantpolynucleotide encoding a mutant luciferase of the present invention, asdescribed above.

In a third aspect there are disclosed vectors comprising apolynucleotide of the second aspect. For instance vectors furthercomprising a replication element which permits replication of the vectorin a suitable host cell and/or a promoter element which permitsexpression of said polynucleotide in a suitable host cell. The promotermay be a constitutive promoter. Optionally the promoter element may betissue- or organ-specific.

In a fourth aspect there is disclosed a host cell containing, ortransformed with, a vector of the third aspect.

Optionally the host cell of the fourth aspect may express one or morefurther luciferases which have a lower K_(m) for ATP than those of thepresent invention, and possibly emit light of a different wavelength,such as to extend the useful range of any assay, and/or allow the use ofa ratiometric assay i.e. one in which the activity of the high K_(m)mutant is compared with that of a further luciferase. The furtherluciferases may be recombinant non-mutant luciferases or recombinantmutant luciferases having a mutation which is such that the K_(m) forATP of the luciferase is decreased with respect to that of thecorresponding non-mutated enzyme (see e.g. WO 96/22376.

Coloured mutants are disclosed in WO 95/18853 and in Ohmiya et al (1996)FEBS Letters 384: 83-86.

In a fifth aspect there is disclosed a process for producing aluciferase of the present invention comprising culturing a host cell asdescribed in the fourth aspect.

In a sixth aspect there is disclosed a single cell organism consistingof a host cell as described above, or a multicellular organ or organismcomprising it. The use of e.g. transgenic higher animals in which theluciferases of the present invention are expressed could allow in vivostudy of [ATP] in different types of cell or tissue as described in moredetail below. In particular, as ATP is present in virtually all livingcells, any type of cell into which luciferase could be cloned, frombacterial to plant or animal, could be studied through the measurementof ATP changes.

Thus in a seventh aspect of invention there is disclosed a method ofassaying the amount of ATP in a material comprising use of a recombinantluciferase as described above.

Preferably the method comprises the following steps (a) the luciferaseis contacted with the material and luciferin; (b) the intensity of lightemitted by the luciferase is measured; and (c) the measurement in step(b) is correlated with the amount of ATP in the material.

The measurement in step (b) may be compared with a control value such asminimise base-line errors.

The assay can be in vitro or in vivo.

More preferably the material itself is a cell, in to which theluciferase is introduced e.g. by transforming the cell with a vector asdescribed above. Alternatively the luciferase may be introduced into thecell by direct injection.

Equally the material measured may be part of a synapse i.e. the ATP isneurotransmitter.

Generally the assay will be most useful for real-time analysis (on atime-scale of seconds e.g. using a CCD camera, photomultiplier orphotodiode) of events initiated by particular stimuli (e.g. addition ofan active agent to the material). In this case the assay can monitorchanges in [ATP] concentration over a relatively short time-scale. Suchmeasurement will not, therefore, be greatly affected by longertime-scale events, such as changes in the concentration of luciferase inthe system. These changes can be correlated with cellular events e.g.tissue necrosis may be associated with falling [ATP], fatigue in musclelikewise. Such continuous assays have hitherto not been possible.

Other possible applications include measuring the effect of drugtreatments on various tissues; toxins and uncoupling agents on oxidativephosphorylation; bacterial infection; metabolic processes and stress(e.g. obesity and exercise); studies of brain activity (e.g. memoryfunction and mental disorders) etc.

If appropriate the [ATP] can be measured periodically (rather thanconstantly) using photographic film.

Essentially the monitoring can be done in ways analogous to thosealready used in the art for other applications e.g. for the photonicdetection of bacterial pathogens in living hosts disclosed by Contag etal (1995) Molecular Microbiology 18(4): 593-603. In that paper aHamamatsu intensified CCD camera was used to visualise SalmonellaTyphimurium expressing luciferase during infection of a mouse. Equally asystem equivalent to PET (positron emission tomography—as used in brainscans) could be used to achieve precise localisation ofluciferase-generated light to allow the metabolism of specific bodyregions to be ascertained.

Generally speaking it will be necessary to introduce luciferin into thesystem being studied. By ‘luciferin’ is meant any co-factor which hasluciferin activity i.e. can be used in conjunction with luciferase tocause light to be emitted in the presence of ATP. The manner by whichthis is introduced in to the system will depend on the system itself.For instance where animal cells are being studied, luciferin may beintroduced by ingestion of luciferin or a precursor thereof by an animalof which the cell is a constituent part. Similarly when the system beingstudied is one or more plant cells, the luciferin may simply beintroduced into the cell by applying a solution of luciferin or aprecursor thereof to a plant of which the cell is a constituent part.

In a final aspect of the invention there is disclosed a test kitcomprising a luciferase discussed above and further comprising one ormore of the following(a) a buffer or dry materials for preparing abuffer; (b) ATP standards; (c) luciferin; (d) Dithiothreitol (e)instructions for carrying out an ATP assay.

The invention will now be further described with reference to thefollowing none-limiting Figures, Sequence Listings and Examples.

Figures

FIG. 1. shows plasmid pPW601 a as described in Example 1.

FIG. 2. for mutant H245A, (a) shows the plot of V against [ATP] and (b)shows 1/V against 1/[ATP] as described in Example 1.

FIG. 3. shows a sequence comparison of one region of P pyralis (Pp) (SEQID NOs: 7, 9 and 11, respectively) and the corresponding region of Lcruciata (Lc) (SEQ ID NOs:8, 10 and 12, respectively as described inExample 2.

FIG. 4 is a graph showing light emission versus ATP concentration formutant H245N.

FIG. 5 . shows the effect of the addition of nutrient broth toluciferase-expressing E. coli cells pre-charged with Luciferin asdescribed in Example 6.

FIGS. 6A and 6B show SEQ ID NO:1 which is the nucleotide sequence of thewild type luc gene from P pyralis.

FIG. 7 shows Seq ID Nos. 2-5 which are the primers used to create themutations H245A, N and Q (Ala, Asn, or Gln—see Seq ID Nos. 2, 3 & 4) andthe equivalent wild-type sequence (Seq ID No 5).

FIGS. 8A and 8B shows SEQ ID NO:6 which is the amino acid sequence of ahigh K_(m) mutant H245Q of the present invention, wherein amino acid 245has been changed to Gln.

EXAMPLES EXAMPLE 1

Production of Recombinant High K_(m) Mutant Luciferase

Except where otherwise stated, the methods employed were as those usedby White et al (1996) Biochemical Journal 319: 342-350, which isconcerned with thermostable mutants.

STARTING MATERIALS: Mutants were generated by site directed mutagenesisof the plasmid pPW601a (FIG. 1) comprising the luciferase gene, luc,from P pyralis. The wild type luc gene from P pyralis is shown at Seq IDNo. 1. Plasmid pPW601a was created by cloning the luc gene BamHI/SstIfragment from pGEM-luc (available from Promega) into pDR540 (availablefrom Pharmacia). The unique XhoI site in the polylinker of the plasmidwas removed to simplify the following procedures.

SITE DIRECTED MUTAGENESIS: Three mutagenic oligonucleotides were used tocreate the mutations H245A, N and Q (Ala, Asn, or Gln—see Seq ID Nos. 2,3 & 4). The equivalent wild-type sequence is shown at Seq ID No. 5. Theoligonucleotides also introduced a silent mutation which destroys aunique Xmn I site in the luc gene—this did not result in an amino acidsubstitution but facilitated mutant selection. The mutagenesis wascarried out in accordance with the kit instructions of kit supplied byClontech laboratories Inc, Palo Alto, Calif. USA.

The amino acid sequence of H245Q is shown in Seq. ID No. 6.

ISOLATION OF PLASMID DNA & TRANSFORMATION: this was carried out by themethod of Brinboim & Doly (1979) Nucleic Acids Research 7: 1513.

CELL CULTURE AND EXTRACTION: E. coli JM109 transformants were grown toan OD₆₀₀=1.0. Aliquots of cells expressing mutant luciferases fromplasmid pPW601a, were subjected to lysis as described in the Promegatechnical bulletin and the lysed extracts were then stored on ice priorto assay.

ASSAY OF Km OF MUTANT LUCIFERASES: luciferase assays were performed at21° C. using 100 μl of assay buffer (20 mM Tricine pH 7.8 containing 2.0mM MgSO₄, 0.1 mM EDTA, 33 mM dithiotheitol, 470 μM D-luciferin and ATPin the concentration range 6.25-800 μM). Each assay contained 5-10 μl ofcrude cell extract.

The plots of V against [ATP] and 1/V against 1/ [ATP] for mutant H245Aare shown in FIG. 2. Such plots kan be used to determine the K_(m.)

The results of each mutation and the recombinant Wild Type are shown inTable 1:

TABLE 1 Luciferase K_(m)MgATP (μM) r Wild Type 66 H245A 442 H245N 623H245Q 1340 A21SL* 65 *A215L is a thermostable mutant in which amino acid215 is substituted with lysine (see WO 96/22376 - SECRETARY OF STATE FORDEFENCE).

ASSAY OF THERMOSTABILITY OF MUTANT LUCIFERASES: the thermostability ofH245N & H245Q was also tested, as compared with mutant A215L and thewild-type. Lysed crude extracts of cells containing luciferase activitywere incubated at 37° C. for set time periods. The thermostability ofthe mutant H245A was found to be very similar to that of the recombinantwild-type. The results are shown in Table 2:

TABLE 2 Remaining activity % Enzyme 0 2 4 8 minutes r Wild 100 64.8 36.626.6 Type A215L 100 101 88 84 H245N 100 96 61 46 H245Q 100 103 78.6 51.5

PURIFICATION: luciferases, e.g. incorporating the H245Q mutation, may bepurified as described in White et al (1996) [supra]. Briefly, the celllysates are centrifuged at 30000 g for 30 mins and the supernatant isfractionated with ammonium sulphate (30-55%). This fraction isresuspended and desalted. The desalted material was passed through ahydroxyapatite column and eluted with 10-200 mM sodium phosphatecontaining dithiothreitol. The luciferase containing eluant is dialysedand applied to a Mono Q anion-exchange column. The enzyme can be elutedwith 0 to 500 mM NaCl.

EXAMPLE 2

Identification of Corresponding High K_(M) Mutants

FIG. 3. shows a sequence comparison of one region of P pyralis and thecorresponding region of L cruciata as describe din Example 2. In thiscase it can be seen that amino acid 245 corresponds to 247.

EXAMPLE 3

Expression of Mutant Luciferase in Mammals

This can be achieved by methods analogous to those disclosed by Liu etal (1997) Nature Biotechnology 15: 167-173. In this method cationicliposomes are used to deliver plasmid DNA containing luciferase a geneto mice.

EXAMPLE 4

An in Vivo ATP Assay in Mammals

This can be carried out by methods analogous to those used by Contag etal (1995) Molecular Microbiology 18(4): 593-603. In this methodluciferase expression in S typhimurium in mice is monitored using a CCDcamera.

EXAMPLE 5

A Kit for an in Vitro ATP Assay

This may be provided as follows: luciferase H245Q; buffer; or drymaterials for preparing a buffer; ATP for standards; luciferin; andinstructions for carrying out an ATP assay.

EXAMPLE 6

Assay for Determining Cell Behaviour

Using a luciferase assay as described in Example 1, a plot of the photoncount versus the ATP concentration was prepared for the H245N mutant.The results are shown in FIG. 4.

In order to demonstrate how the enzyme of the invention can be used instudying cellular behaviour, a sample of recombinant E.coli cells whichexpressed the H245N mutant luciferase were rendered dormant byexhaustion of nutrients. The cells were charged with luciferin by 10minutes immersion in p.H. 5.0 citrate buffer containing 1 mM luciferin.They were then centrifugally washed, resuspended in 1 ml Nutrient Brothand the luminescence monitored. The results are shown in FIG. 5.

Using the mutant luciferase of the invention, the revival and growth offunctional cells could be monitored.

21 1722 base pairs nucleic acid double unknown DNA (genomic) NO NOPhotinus pyralis CDS 4..1653 1 CAAATGGAAG ACGCCAAAAA CATAAAGAAAGGCCCGGCGC CATTCTATCC TCTAGAGGAT 60 GGAACCGCTG GAGAGCAACT GCATAAGGCTATGAAGAGAT ACGCCCTGGT TCCTGGAACA 120 ATTGCTTTTA CAGATGCACA TATCGAGGTGAACATCACGT ACGCGGAATA CTTCGAAATG 180 TCCGTTCGGT TGGCAGAAGC TATGAAACGATATGGGCTGA ATACAAATCA CAGAATCGTC 240 GTATGCAGTG AAAACTCTCT TCAATTCTTTATGCCGGTGT TGGGCGCGTT ATTTATCGGA 300 GTTGCAGTTG CGCCCGCGAA CGACATTTATAATGAACGTG AATTGCTCAA CAGTATGAAC 360 ATTTCGCAGC CTACCGTAGT GTTTGTTTCCAAAAAGGGGT TGCAAAAAAT TTTGAACGTG 420 CAAAAAAAAT TACCAATAAT CCAGAAAATTATTATCATGG ATTCTAAAAC GGATTACCAG 480 GGATTTCAGT CGATGTACAC GTTCGTCACATCTCATCTAC CTCCCGGTTT TAATGAATAC 540 GATTTTGTAC CAGAGTCCTT TGATCGTGACAAAACAATTG CACTGATAAT GAATTCCTCT 600 GGATCTACTG GGTTACCTAA GGGTGTGGCCCTTCCGCATA GAACTGCCTG CGTCAGATTC 660 TCGCATGCCA GAGATCCTAT TTTTGGCAATCAAATCATTC CGGATACTGC GATTTTAAGT 720 GTTGTTCCAT TCCATCACGG TTTTGGAATGTTTACTACAC TCGGATATTT GATATGTGGA 780 TTTCGAGTCG TCTTAATGTA TAGATTTGAAGAAGAGCTGT TTTTACGATC CCTTCAGGAT 840 TACAAAATTC AAAGTGCGTT GCTAGTACCAACCCTATTTT CATTCTTCGC CAAAAGCACT 900 CTGATTGACA AATACGATTT ATCTAATTTACACGAAATTG CTTCTGGGGG CGCACCTCTT 960 TCGAAAGAAG TCGGGGAAGC GGTTGCAAAACGCTTCCATC TTCCAGGGAT ACGACAAGGA 1020 TATGGGCTCA CTGAGACTAC ATCAGCTATTCTGATTACAC CCGAGGGGGA TGATAAACCG 1080 GGCGCGGTCG GTAAAGTTGT TCCATTTTTTGAAGCGAAGG TTGTGGATCT GGATACCGGG 1140 AAAACGCTGG GCGTTAATCA GAGAGGCGAATTATGTGTCA GAGGACCTAT GATTATGTCC 1200 GGTTATGTAA ACAATCCGGA AGCGACCAACGCCTTGATTG ACAAGGATGG ATGGCTACAT 1260 TCTGGAGACA TAGCTTACTG GGACGAAGACGAACACTTCT TCATAGTTGA CCGCTTGAAG 1320 TCTTTAATTA AATACAAAGG ATATCAGGTGGCCCCCGCTG AATTGGAATC GATATTGTTA 1380 CAACACCCCA ACATCTTCGA CGCGGGCGTGGCAGGTCTTC CCGACGATGA CGCCGGTGAA 1440 CTTCCCGCCG CCGTTGTTGT TTTGGAGCACGGAAAGACGA TGACGGAAAA AGAGATCGTG 1500 GATTACGTCG CCAGTCAAGT AACAACCGCGAAAAAGTTGC GCGGAGGAGT TGTGTTTGTG 1560 GACGAAGTAC CGAAAGGTCT TACCGGAAAACTCGACGCAA GAAAAATCAG AGAGATCCTC 1620 ATAAAGGCCA AGAAGGGCGG AAAGTCCAAATTGTAAAATG TAACTGTATT CAGCGATGAC 1680 GAAATTCTTA GCTATTGTAA TCCTCCGAGGCCTCGAGGTC GA 1722 35 base pairs nucleic acid single linear not provided2 GTTGTTCCAT TCCATGCCGG TTTCGGAATG TTTAC 35 35 base pairs nucleic acidsingle linear not provided 3 GTTGTTCCAT TCCATCAGGG TTTCGGAATG TTTAC 3535 base pairs nucleic acid single linear not provided 4 GTTGTTCCATTCCATAACGG TTTCGGAATG TTTAC 35 35 base pairs nucleic acid single linearnot provided 5 GTTGTTCCAT TCCATCACGG TTTTGGAATG TTTAC 35 550 amino acidsamino acid single unknown protein NO Photinus pyralis Modified-site 2456 Met Glu Asp Ala Lys Asn Ile Lys Lys Gly Pro Ala Pro Phe Tyr Pro 1 5 1015 Leu Glu Asp Gly Thr Ala Gly Glu Gln Leu His Lys Ala Met Lys Arg 20 2530 Tyr Ala Leu Val Pro Gly Thr Ile Ala Phe Thr Asp Ala His Ile Glu 35 4045 Val Asn Ile Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala 50 5560 Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg Ile Val Val 65 7075 80 Cys Ser Glu Asn Ser Leu Gln Phe Phe Met Pro Val Leu Gly Ala Leu 8590 95 Phe Ile Gly Val Ala Val Ala Pro Ala Asn Asp Ile Tyr Asn Glu Arg100 105 110 Glu Leu Leu Asn Ser Met Asn Ile Ser Gln Pro Thr Val Val PheVal 115 120 125 Ser Lys Lys Gly Leu Gln Lys Ile Leu Asn Val Gln Lys LysLeu Pro 130 135 140 Ile Ile Gln Lys Ile Ile Ile Met Asp Ser Lys Thr AspTyr Gln Gly 145 150 155 160 Phe Gln Ser Met Tyr Thr Phe Val Thr Ser HisLeu Pro Pro Gly Phe 165 170 175 Asn Glu Tyr Asp Phe Val Pro Glu Ser PheAsp Arg Asp Lys Thr Ile 180 185 190 Ala Leu Ile Met Asn Ser Ser Gly SerThr Gly Leu Pro Lys Gly Val 195 200 205 Ala Leu Pro His Arg Thr Ala CysVal Arg Phe Ser His Ala Arg Asp 210 215 220 Pro Ile Phe Gly Asn Gln IleIle Pro Asp Thr Ala Ile Leu Ser Val 225 230 235 240 Val Pro Phe His GlnGly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu 245 250 255 Ile Cys Gly PheArg Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu 260 265 270 Phe Leu ArgSer Leu Gln Asp Tyr Lys Ile Gln Ser Ala Leu Leu Val 275 280 285 Pro ThrLeu Phe Ser Phe Phe Ala Lys Ser Thr Leu Ile Asp Lys Tyr 290 295 300 AspLeu Ser Asn Leu His Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser 305 310 315320 Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly Ile 325330 335 Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Leu Ile Thr340 345 350 Pro Glu Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val ProPhe 355 360 365 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr LeuGly Val 370 375 380 Asn Gln Arg Gly Glu Leu Cys Val Arg Gly Pro Met IleMet Ser Gly 385 390 395 400 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala LeuIle Asp Lys Asp Gly 405 410 415 Trp Leu His Ser Gly Asp Ile Ala Tyr TrpAsp Glu Asp Glu His Phe 420 425 430 Phe Ile Val Asp Arg Leu Lys Ser LeuIle Lys Tyr Lys Gly Tyr Gln 435 440 445 Val Ala Pro Ala Glu Leu Glu SerIle Leu Leu Gln His Pro Asn Ile 450 455 460 Phe Asp Ala Gly Val Ala GlyLeu Pro Asp Asp Asp Ala Gly Glu Leu 465 470 475 480 Pro Ala Ala Val ValVal Leu Glu His Gly Lys Thr Met Thr Glu Lys 485 490 495 Glu Ile Val AspTyr Val Ala Ser Gln Val Thr Thr Ala Lys Lys Leu 500 505 510 Arg Gly GlyVal Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly 515 520 525 Lys LeuAsp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys 530 535 540 GlyGly Lys Ser Lys Leu 545 550 28 amino acids amino acid linear notprovided 7 Ile Ile Pro Asp Thr Ala Ile Leu Ser Val Val Pro Phe His HisGly 1 5 10 15 Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu Ile Cys 20 25 28amino acids amino acid linear not provided 8 Val Ser Pro Gly Thr Ala ValLeu Thr Val Val Pro Phe His His Gly 1 5 10 15 Phe Gly Met Phe Thr ThrLeu Gly Tyr Leu Ile Cys 20 25 35 amino acids amino acid linear notprovided 9 Ile Asp Lys Tyr Asp Leu Ser Asn Leu His Glu Ile Ala Ser GlyGly 1 5 10 15 Ala Pro Leu Ser Lys Glu Val Gly Glu Ala Val Ala Lys ArgPhe His 20 25 30 Leu Pro Gly 35 35 amino acids amino acid linear notprovided 10 Leu Asn Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser GlyGly 1 5 10 15 Ala Pro Leu Ser Lys Glu Val Gly Glu Ala Val Ala Arg ArgPhe His 20 25 30 Leu Pro Gly 35 40 amino acids amino acid linear notprovided 11 Arg Phe His Leu Pro Gly Ile Arg Gln Gly Tyr Gly Leu Thr GluThr 1 5 10 15 Thr Ser Ala Ile Leu Ile Thr Pro Glu Gly Asp Asp Lys ProGly Ala 20 25 30 Val Gly Lys Val Val Pro Phe Phe 35 40 40 amino acidsamino acid linear not provided 12 Arg Phe Asn Leu Pro Gly Val Arg GlnGly Tyr Gly Leu Thr Glu Thr 1 5 10 15 Thr Ser Ala Ile Ile Ile Thr ProGlu Gly Asp Asp Lys Pro Gly Ala 20 25 30 Ser Gly Lys Val Val Pro Leu Phe35 40 1644 base pairs nucleic acid single linear cDNA not provided CDS1..1644 13 ATG GAA AAC ATG GAA AAC GAT GAA AAT ATT GTA GTT GGA CCT AAACCG 48 Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val Val Gly Pro Lys Pro 15 10 15 TTT TAC CCT ATC GAA GAG GGA TCT GCT GGA ACA CAA TTA CGC AAA TAC96 Phe Tyr Pro Ile Glu Glu Gly Ser Ala Gly Thr Gln Leu Arg Lys Tyr 20 2530 ATG GAG CGA TAT GCA AAA CTT GGC GCA ATT GCT TTT ACA AAT GCA GTT 144Met Glu Arg Tyr Ala Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Val 35 40 45ACT GGT GTT GAT TAT TCT TAC GCC GAA TAC TTG GAG AAA TCA TGT TGT 192 ThrGly Val Asp Tyr Ser Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys 50 55 60 CTAGGA AAA GCT TTG CAA AAT TAT GGT TTG GTT GTT GAT GGC AGA ATT 240 Leu GlyLys Ala Leu Gln Asn Tyr Gly Leu Val Val Asp Gly Arg Ile 65 70 75 80 GCGTTA TGC AGT GAA AAC TGT GAA GAA TTT TTT ATT CCT GTA ATA GCC 288 Ala LeuCys Ser Glu Asn Cys Glu Glu Phe Phe Ile Pro Val Ile Ala 85 90 95 GGA CTGTTT ATA GGT GTA GGT GTT GCA CCC ACT AAT GAG ATT TAC ACT 336 Gly Leu PheIle Gly Val Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr 100 105 110 TTA CGTGAA CTG GTT CAC AGT TTA GGT ATC TCT AAA CCA ACA ATT GTA 384 Leu Arg GluLeu Val His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val 115 120 125 TTT AGTTCT AAA AAA GGC TTA GAT AAA GTT ATA ACA GTA CAG AAA ACA 432 Phe Ser SerLys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr 130 135 140 GTA ACTACT ATT AAA ACC ATT GTT ATA CTA GAT AGC AAA GTT GAT TAT 480 Val Thr ThrIle Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr 145 150 155 160 CGAGGA TAT CAA TGT CTG GAC ACC TTT ATA AAA AGA AAC ACT CCA CCA 528 Arg GlyTyr Gln Cys Leu Asp Thr Phe Ile Lys Arg Asn Thr Pro Pro 165 170 175 GGTTTT CAA GCA TCC AGT TTC AAA ACT GTG GAA GTT GAC CGT AAA GAA 576 Gly PheGln Ala Ser Ser Phe Lys Thr Val Glu Val Asp Arg Lys Glu 180 185 190 CAAGTT GCT CTT ATA ATG AAC TCT TCG GGT TCT ACC GGT TTG CCA AAA 624 Gln ValAla Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys 195 200 205 GGCGTA CAA CTT ACT CAC GAA AAT ACA GTC ACT AGA TTT TCT CAT GCT 672 Gly ValGln Leu Thr His Glu Asn Thr Val Thr Arg Phe Ser His Ala 210 215 220 AGAGAT CCG ATT TAT GGT AAC CAA GTT TCA CCA GGC ACC GCT GTT TTA 720 Arg AspPro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Val Leu 225 230 235 240ACT GTC GTT CCA TTC CAT CAT GGT TTT GGT ATG TTC ACT ACT CTA GGG 768 ThrVal Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly 245 250 255TAT TTA ATT TGT GGT TTT CGT GTT GTA ATG TTA ACA AAA TTC GAT GAA 816 TyrLeu Ile Cys Gly Phe Arg Val Val Met Leu Thr Lys Phe Asp Glu 260 265 270GAA ACA TTT TTA AAA ACT CTA CAA GAT TAT AAA TGT ACA AGT GTT ATT 864 GluThr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Thr Ser Val Ile 275 280 285CTT GTA CCG ACC TTG TTT GCA ATT CTC AAC AAA AGT GAA TTA CTC AAT 912 LeuVal Pro Thr Leu Phe Ala Ile Leu Asn Lys Ser Glu Leu Leu Asn 290 295 300AAA TAC GAT TTG TCA AAT TTA GTT GAG ATT GCA TCT GGC GGA GCA CCT 960 LysTyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro 305 310 315320 TTA TCA AAA GAA GTT GGT GAA GCT GTT GCT AGA CGC TTT AAT CTT CCC 1008Leu Ser Lys Glu Val Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro 325 330335 GGT GTT CGT CAA GGT TAT GGT TTA ACA GAA ACA ACA TCT GCC ATT ATT 1056Gly Val Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile 340 345350 ATT ACA CCA GAA GGA GAC GAT AAA CCA GGA GCT TCT GGA AAA GTC GTG 1104Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val 355 360365 CCG TTG TTT AAA GCA AAA GTT ATT GAT CTT GAT ACC AAA AAA TCT TTA 1152Pro Leu Phe Lys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Ser Leu 370 375380 GGT CCT AAC AGA CGT GGA GAA GTT TGT GTT AAA GGA CCT ATG CTT ATG 1200Gly Pro Asn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met 385 390395 400 AAA GGT TAT GTA AAT AAT CCA GAA GCA ACA AAA GAA CTT ATT GAC GAA1248 Lys Gly Tyr Val Asn Asn Pro Glu Ala Thr Lys Glu Leu Ile Asp Glu 405410 415 GAA GGT TGG CTG CAC ACC GGA GAT ATT GGA TAT TAT GAT GAA GAA AAA1296 Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys 420425 430 CAT TTC TTT ATT GTC GAT CGT TTG AAG TCT TTA ATC AAA TAC AAA GGA1344 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly 435440 445 TAC CAA GTA CCA CCT GCC GAA TTA GAA TCC GTT CTT TTG CAA CAT CCA1392 Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro 450455 460 TCT ATC TTT GAT GCT GGT GTT GCC GGC GTT CCT GAT CCT GTA GCT GGC1440 Ser Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Val Ala Gly 465470 475 480 GAG CTT CCA GGA GCC GTT GTT GTA CTG GAA AGC GGA AAA AAT ATGACC 1488 Glu Leu Pro Gly Ala Val Val Val Leu Glu Ser Gly Lys Asn Met Thr485 490 495 GAA AAA GAA GTA ATG GAT TAT GTT GCA AGT CAA GTT TCA AAT GCAAAA 1536 Glu Lys Glu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys500 505 510 CGT TTA CGT GGT GGT GTT CGT TTT GTG GAT GAA GTA CCT AAA GGTCTT 1584 Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu515 520 525 ACT GGA AAA ATT GAC GGC AGA GCA ATT AGA GAA ATC CTT AAG AAACCA 1632 Thr Gly Lys Ile Asp Gly Arg Ala Ile Arg Glu Ile Leu Lys Lys Pro530 535 540 GTT GCT AAG ATG 1644 Val Ala Lys Met 545 548 amino acidsamino acid linear protein not provided 14 Met Glu Asn Met Glu Asn AspGlu Asn Ile Val Val Gly Pro Lys Pro 1 5 10 15 Phe Tyr Pro Ile Glu GluGly Ser Ala Gly Thr Gln Leu Arg Lys Tyr 20 25 30 Met Glu Arg Tyr Ala LysLeu Gly Ala Ile Ala Phe Thr Asn Ala Val 35 40 45 Thr Gly Val Asp Tyr SerTyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys 50 55 60 Leu Gly Lys Ala Leu GlnAsn Tyr Gly Leu Val Val Asp Gly Arg Ile 65 70 75 80 Ala Leu Cys Ser GluAsn Cys Glu Glu Phe Phe Ile Pro Val Ile Ala 85 90 95 Gly Leu Phe Ile GlyVal Gly Val Ala Pro Thr Asn Glu Ile Tyr Thr 100 105 110 Leu Arg Glu LeuVal His Ser Leu Gly Ile Ser Lys Pro Thr Ile Val 115 120 125 Phe Ser SerLys Lys Gly Leu Asp Lys Val Ile Thr Val Gln Lys Thr 130 135 140 Val ThrThr Ile Lys Thr Ile Val Ile Leu Asp Ser Lys Val Asp Tyr 145 150 155 160Arg Gly Tyr Gln Cys Leu Asp Thr Phe Ile Lys Arg Asn Thr Pro Pro 165 170175 Gly Phe Gln Ala Ser Ser Phe Lys Thr Val Glu Val Asp Arg Lys Glu 180185 190 Gln Val Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys195 200 205 Gly Val Gln Leu Thr His Glu Asn Thr Val Thr Arg Phe Ser HisAla 210 215 220 Arg Asp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr AlaVal Leu 225 230 235 240 Thr Val Val Pro Phe His His Gly Phe Gly Met PheThr Thr Leu Gly 245 250 255 Tyr Leu Ile Cys Gly Phe Arg Val Val Met LeuThr Lys Phe Asp Glu 260 265 270 Glu Thr Phe Leu Lys Thr Leu Gln Asp TyrLys Cys Thr Ser Val Ile 275 280 285 Leu Val Pro Thr Leu Phe Ala Ile LeuAsn Lys Ser Glu Leu Leu Asn 290 295 300 Lys Tyr Asp Leu Ser Asn Leu ValGlu Ile Ala Ser Gly Gly Ala Pro 305 310 315 320 Leu Ser Lys Glu Val GlyGlu Ala Val Ala Arg Arg Phe Asn Leu Pro 325 330 335 Gly Val Arg Gln GlyTyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile 340 345 350 Ile Thr Pro GluGly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val 355 360 365 Pro Leu PheLys Ala Lys Val Ile Asp Leu Asp Thr Lys Lys Ser Leu 370 375 380 Gly ProAsn Arg Arg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met 385 390 395 400Lys Gly Tyr Val Asn Asn Pro Glu Ala Thr Lys Glu Leu Ile Asp Glu 405 410415 Glu Gly Trp Leu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys 420425 430 His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly435 440 445 Tyr Gln Val Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln HisPro 450 455 460 Ser Ile Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro ValAla Gly 465 470 475 480 Glu Leu Pro Gly Ala Val Val Val Leu Glu Ser GlyLys Asn Met Thr 485 490 495 Glu Lys Glu Val Met Asp Tyr Val Ala Ser GlnVal Ser Asn Ala Lys 500 505 510 Arg Leu Arg Gly Gly Val Arg Phe Val AspGlu Val Pro Lys Gly Leu 515 520 525 Thr Gly Lys Ile Asp Gly Arg Ala IleArg Glu Ile Leu Lys Lys Pro 530 535 540 Val Ala Lys Met 545 1644 basepairs nucleic acid both both cDNA not provided CDS 1..1644 15 ATG GAAAAC ATG GAG AAC GAT GAA AAT ATT GTG TAT GGT CCT GAA CCA 48 Met Glu AsnMet Glu Asn Asp Glu Asn Ile Val Tyr Gly Pro Glu Pro 1 5 10 15 TTT TACCCT ATT GAA GAG GGA TCT GCT GGA GCA CAA TTG CGC AAG TAT 96 Phe Tyr ProIle Glu Glu Gly Ser Ala Gly Ala Gln Leu Arg Lys Tyr 20 25 30 ATG GAT CGATAT GCA AAA CTT GGA GCA ATT GCT TTT ACT AAC GCA CTT 144 Met Asp Arg TyrAla Lys Leu Gly Ala Ile Ala Phe Thr Asn Ala Leu 35 40 45 ACC GGT GTC GATTAT ACG TAC GCC GAA TAC TTA GAA AAA TCA TGC TGT 192 Thr Gly Val Asp TyrThr Tyr Ala Glu Tyr Leu Glu Lys Ser Cys Cys 50 55 60 CTA GGA GAG GCT TTAAAG AAT TAT GGT TTG GTT GTT GAT GGA AGA ATT 240 Leu Gly Glu Ala Leu LysAsn Tyr Gly Leu Val Val Asp Gly Arg Ile 65 70 75 80 GCG TTA TGC AGT GAAAAC TGT GAA GAA TTC TTT ATT CCT GTA TTA GCC 288 Ala Leu Cys Ser Glu AsnCys Glu Glu Phe Phe Ile Pro Val Leu Ala 85 90 95 GGT TTA TTT ATA GGT GTCGGT GTG GCT CCA ACT AAT GAG ATT TAC ACT 336 Gly Leu Phe Ile Gly Val GlyVal Ala Pro Thr Asn Glu Ile Tyr Thr 100 105 110 CTA CGT GAA TTG GTT CACAGT TTA GGC ATC TCT AAG CCA ACA ATT GTA 384 Leu Arg Glu Leu Val His SerLeu Gly Ile Ser Lys Pro Thr Ile Val 115 120 125 TTT AGT TCT AAA AAA GGATTA GAT AAA GTT ATA ACT GTA CAA AAA ACG 432 Phe Ser Ser Lys Lys Gly LeuAsp Lys Val Ile Thr Val Gln Lys Thr 130 135 140 GTA ACT GCT ATT AAA ACCATT GTT ATA TTG GAC AGC AAA GTG GAT TAT 480 Val Thr Ala Ile Lys Thr IleVal Ile Leu Asp Ser Lys Val Asp Tyr 145 150 155 160 AGA GGT TAT CAA TCCATG GAC AAC TTT ATT AAA AAA AAC ACT CCA CAA 528 Arg Gly Tyr Gln Ser MetAsp Asn Phe Ile Lys Lys Asn Thr Pro Gln 165 170 175 GGT TTC AAA GGA TCAAGT TTT AAA ACT GTA GAA GTT AAC CGC AAA GAA 576 Gly Phe Lys Gly Ser SerPhe Lys Thr Val Glu Val Asn Arg Lys Glu 180 185 190 CAA GTT GCT CTT ATAATG AAC TCT TCG GGT TCA ACC GGT TTG CCA AAA 624 Gln Val Ala Leu Ile MetAsn Ser Ser Gly Ser Thr Gly Leu Pro Lys 195 200 205 GGT GTG CAA CTT ACTCAT GAA AAT GCA GTC ACT AGA TTT TCT CAC GCT 672 Gly Val Gln Leu Thr HisGlu Asn Ala Val Thr Arg Phe Ser His Ala 210 215 220 AGA GAT CCA ATT TATGGA AAC CAA GTT TCA CCA GGC ACG GCT ATT TTA 720 Arg Asp Pro Ile Tyr GlyAsn Gln Val Ser Pro Gly Thr Ala Ile Leu 225 230 235 240 ACT GTA GTA CCATTC CAT CAT GGT TTT GGT ATG TTT ACT ACT TTA GGC 768 Thr Val Val Pro PheHis His Gly Phe Gly Met Phe Thr Thr Leu Gly 245 250 255 TAT CTA ACT TGTGGT TTT CGT ATT GTC ATG TTA ACG AAA TTT GAC GAA 816 Tyr Leu Thr Cys GlyPhe Arg Ile Val Met Leu Thr Lys Phe Asp Glu 260 265 270 GAG ACT TTT TTAAAA ACA CTG CAA GAT TAC AAA TGT TCA AGC GTT ATT 864 Glu Thr Phe Leu LysThr Leu Gln Asp Tyr Lys Cys Ser Ser Val Ile 275 280 285 CTT GTA CCG ACTTTG TTT GCA ATT CTT AAT AGA AGT GAA TTA CTC GAT 912 Leu Val Pro Thr LeuPhe Ala Ile Leu Asn Arg Ser Glu Leu Leu Asp 290 295 300 AAA TAT GAT TTATCA AAT TTA GTT GAA ATT GCA TCT GGC GGA GCA CCT 960 Lys Tyr Asp Leu SerAsn Leu Val Glu Ile Ala Ser Gly Gly Ala Pro 305 310 315 320 TTA TCT AAAGAA ATT GGT GAA GCT GTT GCT AGA CGT TTT AAT TTA CCG 1008 Leu Ser Lys GluIle Gly Glu Ala Val Ala Arg Arg Phe Asn Leu Pro 325 330 335 GGT GTT CGTCAA GGC TAT GGT TTA ACA GAA ACA ACC TCT GCA ATT ATT 1056 Gly Val Arg GlnGly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Ile 340 345 350 ATC ACA CCGGAA GGC GAT GAT AAA CCA GGT GCT TCT GGC AAA GTT GTG 1104 Ile Thr Pro GluGly Asp Asp Lys Pro Gly Ala Ser Gly Lys Val Val 355 360 365 CCA TTA TTTAAA GCA AAA GTT ATC GAT CTT GAT ACT AAA AAA ACT TTG 1152 Pro Leu Phe LysAla Lys Val Ile Asp Leu Asp Thr Lys Lys Thr Leu 370 375 380 GGC CCG AACAGA CGT GGA GAA GTT TGT GTA AAG GGT CCT ATG CTT ATG 1200 Gly Pro Asn ArgArg Gly Glu Val Cys Val Lys Gly Pro Met Leu Met 385 390 395 400 AAA GGTTAT GTA GAT AAT CCA GAA GCA ACA AGA GAA ATC ATA GAT GAA 1248 Lys Gly TyrVal Asp Asn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu 405 410 415 GAA GGTTGG TTG CAC ACA GGA GAT ATT GGG TAT TAC GAT GAA GAA AAA 1296 Glu Gly TrpLeu His Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys 420 425 430 CAT TTCTTT ATC GTG GAT CGT TTG AAG TCT TTA ATC AAA TAC AAA GGA 1344 His Phe PheIle Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly 435 440 445 TAT CAAGTA CCA CCT GCT GAA TTA GAA TCT GTT CTT TTG CAA CAT CCA 1392 Tyr Gln ValPro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro 450 455 460 AAT ATTTTT GAT GCC GGC GTT GCT GGC GTT CCA GAT CCT ATA GCT GGT 1440 Asn Ile PheAsp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly 465 470 475 480 GAGCTT CCG GGA GCT GTT GTT GTA CTT GAA AAA GGA AAA TCT ATG ACT 1488 Glu LeuPro Gly Ala Val Val Val Leu Glu Lys Gly Lys Ser Met Thr 485 490 495 GAAAAA GAA GTA ATG GAT TAC GTT GCT AGT CAA GTT TCA AAT GCA AAA 1536 Glu LysGlu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys 500 505 510 CGTTTG CGT GGT GGT GTC CGT TTT GTG GAC GAA GTA CCT AAA GGT CTC 1584 Arg LeuArg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys Gly Leu 515 520 525 ACTGGT AAA ATT GAC GGT AAA GCA ATT AGA GAA ATA CTG AAG AAA CCA 1632 Thr GlyLys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu Lys Lys Pro 530 535 540 GTTGCT AAG ATG 1644 Val Ala Lys Met 545 548 amino acids amino acid linearprotein not provided 16 Met Glu Asn Met Glu Asn Asp Glu Asn Ile Val TyrGly Pro Glu Pro 1 5 10 15 Phe Tyr Pro Ile Glu Glu Gly Ser Ala Gly AlaGln Leu Arg Lys Tyr 20 25 30 Met Asp Arg Tyr Ala Lys Leu Gly Ala Ile AlaPhe Thr Asn Ala Leu 35 40 45 Thr Gly Val Asp Tyr Thr Tyr Ala Glu Tyr LeuGlu Lys Ser Cys Cys 50 55 60 Leu Gly Glu Ala Leu Lys Asn Tyr Gly Leu ValVal Asp Gly Arg Ile 65 70 75 80 Ala Leu Cys Ser Glu Asn Cys Glu Glu PhePhe Ile Pro Val Leu Ala 85 90 95 Gly Leu Phe Ile Gly Val Gly Val Ala ProThr Asn Glu Ile Tyr Thr 100 105 110 Leu Arg Glu Leu Val His Ser Leu GlyIle Ser Lys Pro Thr Ile Val 115 120 125 Phe Ser Ser Lys Lys Gly Leu AspLys Val Ile Thr Val Gln Lys Thr 130 135 140 Val Thr Ala Ile Lys Thr IleVal Ile Leu Asp Ser Lys Val Asp Tyr 145 150 155 160 Arg Gly Tyr Gln SerMet Asp Asn Phe Ile Lys Lys Asn Thr Pro Gln 165 170 175 Gly Phe Lys GlySer Ser Phe Lys Thr Val Glu Val Asn Arg Lys Glu 180 185 190 Gln Val AlaLeu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys 195 200 205 Gly ValGln Leu Thr His Glu Asn Ala Val Thr Arg Phe Ser His Ala 210 215 220 ArgAsp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu 225 230 235240 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly 245250 255 Tyr Leu Thr Cys Gly Phe Arg Ile Val Met Leu Thr Lys Phe Asp Glu260 265 270 Glu Thr Phe Leu Lys Thr Leu Gln Asp Tyr Lys Cys Ser Ser ValIle 275 280 285 Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Arg Ser Glu LeuLeu Asp 290 295 300 Lys Tyr Asp Leu Ser Asn Leu Val Glu Ile Ala Ser GlyGly Ala Pro 305 310 315 320 Leu Ser Lys Glu Ile Gly Glu Ala Val Ala ArgArg Phe Asn Leu Pro 325 330 335 Gly Val Arg Gln Gly Tyr Gly Leu Thr GluThr Thr Ser Ala Ile Ile 340 345 350 Ile Thr Pro Glu Gly Asp Asp Lys ProGly Ala Ser Gly Lys Val Val 355 360 365 Pro Leu Phe Lys Ala Lys Val IleAsp Leu Asp Thr Lys Lys Thr Leu 370 375 380 Gly Pro Asn Arg Arg Gly GluVal Cys Val Lys Gly Pro Met Leu Met 385 390 395 400 Lys Gly Tyr Val AspAsn Pro Glu Ala Thr Arg Glu Ile Ile Asp Glu 405 410 415 Glu Gly Trp LeuHis Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Glu Lys 420 425 430 His Phe PheIle Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly 435 440 445 Tyr GlnVal Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro 450 455 460 AsnIle Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Ile Ala Gly 465 470 475480 Glu Leu Pro Gly Ala Val Val Val Leu Glu Lys Gly Lys Ser Met Thr 485490 495 Glu Lys Glu Val Met Asp Tyr Val Ala Ser Gln Val Ser Asn Ala Lys500 505 510 Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys GlyLeu 515 520 525 Thr Gly Lys Ile Asp Gly Lys Ala Ile Arg Glu Ile Leu LysLys Pro 530 535 540 Val Ala Lys Met 545 2009 base pairs nucleic acidboth both cDNA not provided CDS 69..1715 17 GGAATTCGGC ACGAGGTTACAATTACAACT TCGAAGTCCC TAAACGGTAG AGGAAAAGTT 60 TTTGAAAA ATG GAA ATG GAAAAG GAG GAG AAT GTT GTA TAT GGC CCT CTG 110 Met Glu Met Glu Lys Glu GluAsn Val Val Tyr Gly Pro Leu 1 5 10 CCA TTC TAC CCC ATT GAA GAA GGA TCAGCT GGA ATT CAG TTG CAT AAG 158 Pro Phe Tyr Pro Ile Glu Glu Gly Ser AlaGly Ile Gln Leu His Lys 15 20 25 30 TAC ATG CAT CAA TAT GCC AAA CTT GGAGCA ATT GCT TTT AGT AAC GCC 206 Tyr Met His Gln Tyr Ala Lys Leu Gly AlaIle Ala Phe Ser Asn Ala 35 40 45 CTT ACT GGA GTT GAC ATT TCT TAC CAA GAATAC TTT GAT ATT ACA TGT 254 Leu Thr Gly Val Asp Ile Ser Tyr Gln Glu TyrPhe Asp Ile Thr Cys 50 55 60 CGT TTA GCT GAG GCC ATG AAA AAC TTT GGT ATGAAA CCG GAA GAA CAT 302 Arg Leu Ala Glu Ala Met Lys Asn Phe Gly Met LysPro Glu Glu His 65 70 75 ATT GCT TTG TGC AGT GAA AAT TGT GAA GAA TTT TTCATC CCT GTA CTT 350 Ile Ala Leu Cys Ser Glu Asn Cys Glu Glu Phe Phe IlePro Val Leu 80 85 90 GCT GGT CTT TAC ATT GGG GTA GCT GTT GCA CCT ACT AATGAA ATT TAC 398 Ala Gly Leu Tyr Ile Gly Val Ala Val Ala Pro Thr Asn GluIle Tyr 95 100 105 110 ACA TTG CGT GAA CTT AAT CAT AGT TTG GGC ATC GCACAA CCA ACT ATT 446 Thr Leu Arg Glu Leu Asn His Ser Leu Gly Ile Ala GlnPro Thr Ile 115 120 125 GTA TTC AGC TCC AGA AAA GGC TTA CCT AAA GTT TTAGAA GTG CAA AAA 494 Val Phe Ser Ser Arg Lys Gly Leu Pro Lys Val Leu GluVal Gln Lys 130 135 140 ACA GTT ACA TGC ATC AAA AAA ATT GTT ATT TTA GATAGT AAA GTA AAC 542 Thr Val Thr Cys Ile Lys Lys Ile Val Ile Leu Asp SerLys Val Asn 145 150 155 TTT GGG GGC CAC GAT TGT ATG GAA ACT TTT ATT AAGAAA CAT GTA GAA 590 Phe Gly Gly His Asp Cys Met Glu Thr Phe Ile Lys LysHis Val Glu 160 165 170 TTA GGT TTT CAA CCA AGT AGC TTT GTA CCC ATT GATGTA AAG AAC CGT 638 Leu Gly Phe Gln Pro Ser Ser Phe Val Pro Ile Asp ValLys Asn Arg 175 180 185 190 AAA CAA CAC GTT GCT TTG CTT ATG AAT TCT TCTGGC TCT ACT GGT TTA 686 Lys Gln His Val Ala Leu Leu Met Asn Ser Ser GlySer Thr Gly Leu 195 200 205 CCT AAA GGT GTA CGA ATT ACC CAC GAA GGT GCAGTT ACA AGA TTC TCA 734 Pro Lys Gly Val Arg Ile Thr His Glu Gly Ala ValThr Arg Phe Ser 210 215 220 CAC GCT AAG GAT CCA ATT TAC GGA AAC CAA GTTTCA CCT GGT ACT GCT 782 His Ala Lys Asp Pro Ile Tyr Gly Asn Gln Val SerPro Gly Thr Ala 225 230 235 ATT TTA ACT GTC GTT CCG TTC CAT CAT GGA TTTGGA ATG TTT ACC ACT 830 Ile Leu Thr Val Val Pro Phe His His Gly Phe GlyMet Phe Thr Thr 240 245 250 TTA GGA TAC TTT GCT TGT GGA TAC CGT GTT GTAATG TTA ACA AAA TTT 878 Leu Gly Tyr Phe Ala Cys Gly Tyr Arg Val Val MetLeu Thr Lys Phe 255 260 265 270 GAT GAA GAA CTA TTT TTG AGA ACT TTG CAAGAT TAT AAG TGT ACC AGT 926 Asp Glu Glu Leu Phe Leu Arg Thr Leu Gln AspTyr Lys Cys Thr Ser 275 280 285 GTT ATT CTG GTA CCA ACG TTA TTT GCT ATTCTC AAC AAG AGT GAA TTG 974 Val Ile Leu Val Pro Thr Leu Phe Ala Ile LeuAsn Lys Ser Glu Leu 290 295 300 ATC GAT AAG TTC GAT TTA TCT AAT CTA ACTGAA ATT GCT TCT GGT GGA 1022 Ile Asp Lys Phe Asp Leu Ser Asn Leu Thr GluIle Ala Ser Gly Gly 305 310 315 GCT CCT TTG GCA AAA GAA GTT GGC GAA GCAGTC GCT AGA AGA TTT AAT 1070 Ala Pro Leu Ala Lys Glu Val Gly Glu Ala ValAla Arg Arg Phe Asn 320 325 330 CTA CCC GGT GTC CGT CAG GGT TAC GGA TTAACA GAA ACG ACA TCT GCA 1118 Leu Pro Gly Val Arg Gln Gly Tyr Gly Leu ThrGlu Thr Thr Ser Ala 335 340 345 350 TTT ATT ATT ACC CCA GAA GGT GAT GATAAA CCT GGA GCA TCT GGA AAA 1166 Phe Ile Ile Thr Pro Glu Gly Asp Asp LysPro Gly Ala Ser Gly Lys 355 360 365 GTA GTA CCC TTA TTC AAA GTA AAA GTTATT GAT CTT GAC ACT AAA AAA 1214 Val Val Pro Leu Phe Lys Val Lys Val IleAsp Leu Asp Thr Lys Lys 370 375 380 ACT TTG GGT GTC AAC CGA CGA GGA GAGATC TGT GTA AAA GGA CCC AGT 1262 Thr Leu Gly Val Asn Arg Arg Gly Glu IleCys Val Lys Gly Pro Ser 385 390 395 CTT ATG TTA GGC TAC TCG AAC AAT CCGGAA GCA ACA AGA GAA ACT ATT 1310 Leu Met Leu Gly Tyr Ser Asn Asn Pro GluAla Thr Arg Glu Thr Ile 400 405 410 GAT GAA GAG GGT TGG TTG CAC ACA GGAGAT ATT GGA TAT TAC GAC GAA 1358 Asp Glu Glu Gly Trp Leu His Thr Gly AspIle Gly Tyr Tyr Asp Glu 415 420 425 430 GAC GAA CAT TTC TTC ATT GTC GATCGT TTG AAA TCA TTA ATC AAA TAC 1406 Asp Glu His Phe Phe Ile Val Asp ArgLeu Lys Ser Leu Ile Lys Tyr 435 440 445 AAG GGG TAC CAG GTA CCA CCT GCTGAA TTG GAA TCC GTT CTT TTG CAA 1454 Lys Gly Tyr Gln Val Pro Pro Ala GluLeu Glu Ser Val Leu Leu Gln 450 455 460 CAT CCA AAT ATA TTT GAT GCT GGTGTG GCT GGT GTC CCC GAT CCC GAT 1502 His Pro Asn Ile Phe Asp Ala Gly ValAla Gly Val Pro Asp Pro Asp 465 470 475 GCT GGC GAA CTT CCA GGG GCT GTAGTT GTA ATG GAA AAA GGA AAA ACT 1550 Ala Gly Glu Leu Pro Gly Ala Val ValVal Met Glu Lys Gly Lys Thr 480 485 490 ATG ACT GAA AAG GAA ATT GTG GATTAT GTT AAT AGT CAA GTA GTG AAC 1598 Met Thr Glu Lys Glu Ile Val Asp TyrVal Asn Ser Gln Val Val Asn 495 500 505 510 CAC AAA CGT CTG CGT GGT GGCGTT CGT TTT GTG GAT GAA GTA CCT AAA 1646 His Lys Arg Leu Arg Gly Gly ValArg Phe Val Asp Glu Val Pro Lys 515 520 525 GGT CTA ACT GGT AAA ATT GATGCT AAA GTA ATT AGA GAA ATT CTT AAG 1694 Gly Leu Thr Gly Lys Ile Asp AlaLys Val Ile Arg Glu Ile Leu Lys 530 535 540 AAA CCA CAA GCC AAG ATGTAAATCAGTC AAAATGCTAT TCATGTAACT 1742 Lys Pro Gln Ala Lys Met 545AAACTACTCA TAAGAAGACA ATTTAAAATT AAGTCATTAC ACACTTAGTG TTATATCTCA 1802AAAGTAGTGG GAGTTTGACA TTTATCTCAA TAATTTATCG AATGGATGCT TGTATTAGTT 1862TCTTATTGTT AATTATAGCT TTAAAGAACG ACTCCTTTAA TATATATTTA CTTGCATTCC 1922AATGGTTATA TTGTAACGGG CACGTTTCCC TGATATGTGT GAAATATACG TCAATTGCAT 1982TATTAAAAAA AAAAAAAAAA AAAAAAA 2009 548 amino acids amino acid linearprotein not provided 18 Met Glu Met Glu Lys Glu Glu Asn Val Val Tyr GlyPro Leu Pro Phe 1 5 10 15 Tyr Pro Ile Glu Glu Gly Ser Ala Gly Ile GlnLeu His Lys Tyr Met 20 25 30 His Gln Tyr Ala Lys Leu Gly Ala Ile Ala PheSer Asn Ala Leu Thr 35 40 45 Gly Val Asp Ile Ser Tyr Gln Glu Tyr Phe AspIle Thr Cys Arg Leu 50 55 60 Ala Glu Ala Met Lys Asn Phe Gly Met Lys ProGlu Glu His Ile Ala 65 70 75 80 Leu Cys Ser Glu Asn Cys Glu Glu Phe PheIle Pro Val Leu Ala Gly 85 90 95 Leu Tyr Ile Gly Val Ala Val Ala Pro ThrAsn Glu Ile Tyr Thr Leu 100 105 110 Arg Glu Leu Asn His Ser Leu Gly IleAla Gln Pro Thr Ile Val Phe 115 120 125 Ser Ser Arg Lys Gly Leu Pro LysVal Leu Glu Val Gln Lys Thr Val 130 135 140 Thr Cys Ile Lys Lys Ile ValIle Leu Asp Ser Lys Val Asn Phe Gly 145 150 155 160 Gly His Asp Cys MetGlu Thr Phe Ile Lys Lys His Val Glu Leu Gly 165 170 175 Phe Gln Pro SerSer Phe Val Pro Ile Asp Val Lys Asn Arg Lys Gln 180 185 190 His Val AlaLeu Leu Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys 195 200 205 Gly ValArg Ile Thr His Glu Gly Ala Val Thr Arg Phe Ser His Ala 210 215 220 LysAsp Pro Ile Tyr Gly Asn Gln Val Ser Pro Gly Thr Ala Ile Leu 225 230 235240 Thr Val Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly 245250 255 Tyr Phe Ala Cys Gly Tyr Arg Val Val Met Leu Thr Lys Phe Asp Glu260 265 270 Glu Leu Phe Leu Arg Thr Leu Gln Asp Tyr Lys Cys Thr Ser ValIle 275 280 285 Leu Val Pro Thr Leu Phe Ala Ile Leu Asn Lys Ser Glu LeuIle Asp 290 295 300 Lys Phe Asp Leu Ser Asn Leu Thr Glu Ile Ala Ser GlyGly Ala Pro 305 310 315 320 Leu Ala Lys Glu Val Gly Glu Ala Val Ala ArgArg Phe Asn Leu Pro 325 330 335 Gly Val Arg Gln Gly Tyr Gly Leu Thr GluThr Thr Ser Ala Phe Ile 340 345 350 Ile Thr Pro Glu Gly Asp Asp Lys ProGly Ala Ser Gly Lys Val Val 355 360 365 Pro Leu Phe Lys Val Lys Val IleAsp Leu Asp Thr Lys Lys Thr Leu 370 375 380 Gly Val Asn Arg Arg Gly GluIle Cys Val Lys Gly Pro Ser Leu Met 385 390 395 400 Leu Gly Tyr Ser AsnAsn Pro Glu Ala Thr Arg Glu Thr Ile Asp Glu 405 410 415 Glu Gly Trp LeuHis Thr Gly Asp Ile Gly Tyr Tyr Asp Glu Asp Glu 420 425 430 His Phe PheIle Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly 435 440 445 Tyr GlnVal Pro Pro Ala Glu Leu Glu Ser Val Leu Leu Gln His Pro 450 455 460 AsnIle Phe Asp Ala Gly Val Ala Gly Val Pro Asp Pro Asp Ala Gly 465 470 475480 Glu Leu Pro Gly Ala Val Val Val Met Glu Lys Gly Lys Thr Met Thr 485490 495 Glu Lys Glu Ile Val Asp Tyr Val Asn Ser Gln Val Val Asn His Lys500 505 510 Arg Leu Arg Gly Gly Val Arg Phe Val Asp Glu Val Pro Lys GlyLeu 515 520 525 Thr Gly Lys Ile Asp Ala Lys Val Ile Arg Glu Ile Leu LysLys Pro 530 535 540 Gln Ala Lys Met 545 1725 base pairs nucleic acidboth linear cDNA not provided CDS 32..1675 19 GAGACACTAA CGCGCTAATATCATTGCAAG A ATG GAA GAT GCA AAA AAT ATT 52 Met Glu Asp Ala Lys Asn Ile1 5 ATG CAC GGT CCA GCG CCA TTC TAT CCT TTG GAG GAT GGA ACT GCT GGA 100Met His Gly Pro Ala Pro Phe Tyr Pro Leu Glu Asp Gly Thr Ala Gly 10 15 20GAA CAA TTG CAC AAA GCA ATG AAG AGG TAT GCA CAG GTT CCA GGG ACA 148 GluGln Leu His Lys Ala Met Lys Arg Tyr Ala Gln Val Pro Gly Thr 25 30 35 ATTGCT TTT ACT GAT GCG CAT GCA GAG GTA AAT ATT ACA TAT TCC GAA 196 Ile AlaPhe Thr Asp Ala His Ala Glu Val Asn Ile Thr Tyr Ser Glu 40 45 50 55 TATTTT GAA ATG GCT TGC CGG TTA GCC GAA ACT ATG AAG AGG TAC GGA 244 Tyr PheGlu Met Ala Cys Arg Leu Ala Glu Thr Met Lys Arg Tyr Gly 60 65 70 CTT GGTTTA CAA CAC CAC ATT GCT GTT TGT AGC GAA AAT TCT CTT CAG 292 Leu Gly LeuGln His His Ile Ala Val Cys Ser Glu Asn Ser Leu Gln 75 80 85 TTT TTT ATGCCT GTA TGC GGG GCT CTA TTT ATT GGA GTT GGA GTT GCA 340 Phe Phe Met ProVal Cys Gly Ala Leu Phe Ile Gly Val Gly Val Ala 90 95 100 TCA ACA AATGAT ATT TAC AAT GAA CGT GAA TTA TAC AAC AGT TTG TCC 388 Ser Thr Asn AspIle Tyr Asn Glu Arg Glu Leu Tyr Asn Ser Leu Ser 105 110 115 ATA TCA CAACCT ACA ATA GTA TCC TGT TCC AAA AGA GCG CTG CAA AAA 436 Ile Ser Gln ProThr Ile Val Ser Cys Ser Lys Arg Ala Leu Gln Lys 120 125 130 135 ATC CTAGGG GTA CAA AAG AAA TTA CCT ATA ATT CAG AAA ATT GTT ATT 484 Ile Leu GlyVal Gln Lys Lys Leu Pro Ile Ile Gln Lys Ile Val Ile 140 145 150 CTG GATTCT CGA GAG GAT TAT ATG GGG AAA CAA TCT ATG TAC TCG TTC 532 Leu Asp SerArg Glu Asp Tyr Met Gly Lys Gln Ser Met Tyr Ser Phe 155 160 165 ATT GAATCT CAT TTA CCT GCA GGT TTT AAT GAA TAT GAT TAC ATA CCG 580 Ile Glu SerHis Leu Pro Ala Gly Phe Asn Glu Tyr Asp Tyr Ile Pro 170 175 180 GAT TCATTT GAC CGC GAA ACA GCA ACA GCA CTT ATA ATG AAT TCA TCG 628 Asp Ser PheAsp Arg Glu Thr Ala Thr Ala Leu Ile Met Asn Ser Ser 185 190 195 GGA TCTACT GGA TTG CCC AAG GGA GTT GAG CTT ACT CAC CAA AAT GTG 676 Gly Ser ThrGly Leu Pro Lys Gly Val Glu Leu Thr His Gln Asn Val 200 205 210 215 TGTGTT AGA TTT TCT CAC TGC AGA GAT CCT GTG TTT GGT AAT CAA ATT 724 Cys ValArg Phe Ser His Cys Arg Asp Pro Val Phe Gly Asn Gln Ile 220 225 230 ATTCCC GAT ACT GCG ATT TTA ACA GTT ATA CCA TTT CAT CAT GGT TTT 772 Ile ProAsp Thr Ala Ile Leu Thr Val Ile Pro Phe His His Gly Phe 235 240 245 GGAATG TTT ACA ACA CTA GGA TAT TTA ACG TGT GGA TTT CGT ATT GTG 820 Gly MetPhe Thr Thr Leu Gly Tyr Leu Thr Cys Gly Phe Arg Ile Val 250 255 260 CTTATG TAT AGA TTT GAA GAG GAA TTA TTT TTA CGA TCA CTT CAA GAT 868 Leu MetTyr Arg Phe Glu Glu Glu Leu Phe Leu Arg Ser Leu Gln Asp 265 270 275 TATAAA ATT CAA AGT GCG TTG CTG GTA CCT ACT CTA TTT TCA TTC TTT 916 Tyr LysIle Gln Ser Ala Leu Leu Val Pro Thr Leu Phe Ser Phe Phe 280 285 290 295GCC AAA AGC ACC TTA GTC GAT AAA TAC GAT TTA TCC AAC TTA CAT GAA 964 AlaLys Ser Thr Leu Val Asp Lys Tyr Asp Leu Ser Asn Leu His Glu 300 305 310ATT GCG TCT GGT GGA GCT CCC CTC GCG AAA GAA GTT GGA GAA GCT GTA 1012 IleAla Ser Gly Gly Ala Pro Leu Ala Lys Glu Val Gly Glu Ala Val 315 320 325GCA AAA CGT TTT AAG CTG CCG GGA ATA CGA CAA GGG TAT GGA CTT ACT 1060 AlaLys Arg Phe Lys Leu Pro Gly Ile Arg Gln Gly Tyr Gly Leu Thr 330 335 340GAA ACT ACC TCA GCT ATT ATA ATT ACA CCA GAA GGG GAT GAT AAA CCA 1108 GluThr Thr Ser Ala Ile Ile Ile Thr Pro Glu Gly Asp Asp Lys Pro 345 350 355GGA GCA TGT GGT AAA GTT GTT CCA TTC TTT TCT GCC AAA ATT GTT GAT 1156 GlyAla Cys Gly Lys Val Val Pro Phe Phe Ser Ala Lys Ile Val Asp 360 365 370375 CTG GAT ACG GGT AAA ACT TTG GGT GTT AAT CAG AGG GGG GAA TTA TGT 1204Leu Asp Thr Gly Lys Thr Leu Gly Val Asn Gln Arg Gly Glu Leu Cys 380 385390 GTG AAA GGC CCA ATG ATA ATG AAG GGT TAC GTA AAC AAC CCA GAA GCA 1252Val Lys Gly Pro Met Ile Met Lys Gly Tyr Val Asn Asn Pro Glu Ala 395 400405 ACA AGT GCA TTG ATA GAC AAA GAT GGT TGG TTA CAC TCT GGT GAC ATA 1300Thr Ser Ala Leu Ile Asp Lys Asp Gly Trp Leu His Ser Gly Asp Ile 410 415420 GCT TAC TAC GAC AAA GAT GGT CAC TTC TTC ATA GTA GAT CGT TTG AAA 1348Ala Tyr Tyr Asp Lys Asp Gly His Phe Phe Ile Val Asp Arg Leu Lys 425 430435 TCG TTA ATT AAA TAC AAA GGT TAT CAG GTA CCG CCT GCC GAA TTA GAA 1396Ser Leu Ile Lys Tyr Lys Gly Tyr Gln Val Pro Pro Ala Glu Leu Glu 440 445450 455 TCG ATA TTG CTG CAA CAT CCC TTC ATA TTT GAT GCA GGT GTT GCA GGA1444 Ser Ile Leu Leu Gln His Pro Phe Ile Phe Asp Ala Gly Val Ala Gly 460465 470 ATT CCC GAC CCA GAT GCC GGT GAA CTT CCT GCA GCC GTT GTT GTC TTA1492 Ile Pro Asp Pro Asp Ala Gly Glu Leu Pro Ala Ala Val Val Val Leu 475480 485 GAG GAA GGC AAA ACG ATG ACT GAA CAA GAA GTG ATG GAT TAT GTT GCG1540 Glu Glu Gly Lys Thr Met Thr Glu Gln Glu Val Met Asp Tyr Val Ala 490495 500 GGA CAA GTA ACT GCT TCT AAG CGT TTA CGT GGA GGA GTT AAG TTT GTG1588 Gly Gln Val Thr Ala Ser Lys Arg Leu Arg Gly Gly Val Lys Phe Val 505510 515 GAC GAA GTA CCT AAA GGT CTA ACT GGA AAG ATT GAT GGA AGA AAA ATC1636 Asp Glu Val Pro Lys Gly Leu Thr Gly Lys Ile Asp Gly Arg Lys Ile 520525 530 535 AGG GAG ATC CTT ATG ATG GGA AAA AAA TCC AAA TTG TAATTCCTTC1682 Arg Glu Ile Leu Met Met Gly Lys Lys Ser Lys Leu 540 545 GGTTTACTATATTCTAACGA AATTTCTACT ACCATAAACA ATC 1725 547 amino acids amino acidlinear protein not provided 20 Met Glu Asp Ala Lys Asn Ile Met His GlyPro Ala Pro Phe Tyr Pro 1 5 10 15 Leu Glu Asp Gly Thr Ala Gly Glu GlnLeu His Lys Ala Met Lys Arg 20 25 30 Tyr Ala Gln Val Pro Gly Thr Ile AlaPhe Thr Asp Ala His Ala Glu 35 40 45 Val Asn Ile Thr Tyr Ser Glu Tyr PheGlu Met Ala Cys Arg Leu Ala 50 55 60 Glu Thr Met Lys Arg Tyr Gly Leu GlyLeu Gln His His Ile Ala Val 65 70 75 80 Cys Ser Glu Asn Ser Leu Gln PhePhe Met Pro Val Cys Gly Ala Leu 85 90 95 Phe Ile Gly Val Gly Val Ala SerThr Asn Asp Ile Tyr Asn Glu Arg 100 105 110 Glu Leu Tyr Asn Ser Leu SerIle Ser Gln Pro Thr Ile Val Ser Cys 115 120 125 Ser Lys Arg Ala Leu GlnLys Ile Leu Gly Val Gln Lys Lys Leu Pro 130 135 140 Ile Ile Gln Lys IleVal Ile Leu Asp Ser Arg Glu Asp Tyr Met Gly 145 150 155 160 Lys Gln SerMet Tyr Ser Phe Ile Glu Ser His Leu Pro Ala Gly Phe 165 170 175 Asn GluTyr Asp Tyr Ile Pro Asp Ser Phe Asp Arg Glu Thr Ala Thr 180 185 190 AlaLeu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val 195 200 205Glu Leu Thr His Gln Asn Val Cys Val Arg Phe Ser His Cys Arg Asp 210 215220 Pro Val Phe Gly Asn Gln Ile Ile Pro Asp Thr Ala Ile Leu Thr Val 225230 235 240 Ile Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly TyrLeu 245 250 255 Thr Cys Gly Phe Arg Ile Val Leu Met Tyr Arg Phe Glu GluGlu Leu 260 265 270 Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser AlaLeu Leu Val 275 280 285 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr LeuVal Asp Lys Tyr 290 295 300 Asp Leu Ser Asn Leu His Glu Ile Ala Ser GlyGly Ala Pro Leu Ala 305 310 315 320 Lys Glu Val Gly Glu Ala Val Ala LysArg Phe Lys Leu Pro Gly Ile 325 330 335 Arg Gln Gly Tyr Gly Leu Thr GluThr Thr Ser Ala Ile Ile Ile Thr 340 345 350 Pro Glu Gly Asp Asp Lys ProGly Ala Cys Gly Lys Val Val Pro Phe 355 360 365 Phe Ser Ala Lys Ile ValAsp Leu Asp Thr Gly Lys Thr Leu Gly Val 370 375 380 Asn Gln Arg Gly GluLeu Cys Val Lys Gly Pro Met Ile Met Lys Gly 385 390 395 400 Tyr Val AsnAsn Pro Glu Ala Thr Ser Ala Leu Ile Asp Lys Asp Gly 405 410 415 Trp LeuHis Ser Gly Asp Ile Ala Tyr Tyr Asp Lys Asp Gly His Phe 420 425 430 PheIle Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln 435 440 445Val Pro Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Phe Ile 450 455460 Phe Asp Ala Gly Val Ala Gly Ile Pro Asp Pro Asp Ala Gly Glu Leu 465470 475 480 Pro Ala Ala Val Val Val Leu Glu Glu Gly Lys Thr Met Thr GluGln 485 490 495 Glu Val Met Asp Tyr Val Ala Gly Gln Val Thr Ala Ser LysArg Leu 500 505 510 Arg Gly Gly Val Lys Phe Val Asp Glu Val Pro Lys GlyLeu Thr Gly 515 520 525 Lys Ile Asp Gly Arg Lys Ile Arg Glu Ile Leu MetMet Gly Lys Lys 530 535 540 Ser Lys Leu 545 550 amino acids amino acidlinear protein not provided 21 Met Glu Asp Ala Lys Asn Ile Lys Lys GlyPro Ala Pro Phe Tyr Pro 1 5 10 15 Leu Glu Asp Gly Thr Ala Gly Glu GlnLeu His Lys Ala Met Lys Arg 20 25 30 Tyr Ala Leu Val Pro Gly Thr Ile AlaPhe Thr Asp Ala His Ile Glu 35 40 45 Val Asn Ile Thr Tyr Ala Glu Tyr PheGlu Met Ser Val Arg Leu Ala 50 55 60 Glu Ala Met Lys Arg Tyr Gly Leu AsnThr Asn His Arg Ile Val Val 65 70 75 80 Cys Ser Glu Asn Ser Leu Gln PhePhe Met Pro Val Leu Gly Ala Leu 85 90 95 Phe Ile Gly Val Ala Val Ala ProAla Asn Asp Ile Tyr Asn Glu Arg 100 105 110 Glu Leu Leu Asn Ser Met AsnIle Ser Gln Pro Thr Val Val Phe Val 115 120 125 Ser Lys Lys Gly Leu GlnLys Ile Leu Asn Val Gln Lys Lys Leu Pro 130 135 140 Ile Ile Gln Lys IleIle Ile Met Asp Ser Lys Thr Asp Tyr Gln Gly 145 150 155 160 Phe Gln SerMet Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe 165 170 175 Asn GluTyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr Ile 180 185 190 AlaLeu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val 195 200 205Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp 210 215220 Pro Ile Phe Gly Asn Gln Ile Ile Pro Asp Thr Ala Ile Leu Ser Val 225230 235 240 Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly TyrLeu 245 250 255 Ile Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu GluGlu Leu 260 265 270 Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser AlaLeu Leu Val 275 280 285 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr LeuIle Asp Lys Tyr 290 295 300 Asp Leu Ser Asn Leu His Glu Ile Ala Ser GlyGly Ala Pro Leu Ser 305 310 315 320 Lys Glu Val Gly Glu Ala Val Ala LysArg Phe His Leu Pro Gly Ile 325 330 335 Arg Gln Gly Tyr Gly Leu Thr GluThr Thr Ser Ala Ile Leu Ile Thr 340 345 350 Pro Glu Gly Asp Asp Lys ProGly Ala Val Gly Lys Val Val Pro Phe 355 360 365 Phe Glu Ala Lys Val ValAsp Leu Asp Thr Gly Lys Thr Leu Gly Val 370 375 380 Asn Gln Arg Gly GluLeu Cys Val Arg Gly Pro Met Ile Met Ser Gly 385 390 395 400 Tyr Val AsnAsn Pro Glu Ala Thr Asn Ala Leu Ile Asp Lys Asp Gly 405 410 415 Trp LeuHis Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu His Phe 420 425 430 PheIle Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln 435 440 445Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile 450 455460 Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu 465470 475 480 Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr GluLys 485 490 495 Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala LysLys Leu 500 505 510 Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys GlyLeu Thr Gly 515 520 525 Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu IleLys Ala Lys Lys 530 535 540 Gly Gly Lys Ser Lys Leu 545 550

What is claimed is:
 1. A recombinant mutant luciferase having 70% or more homology to a luciferase of Photinus pyralis (SEQ ID NO: 21), Luciola cruciata (SEQ ID NO:14), Luciola lateralis (SEQ ID NO:16), Luciola mingrelica (SEQ ID NO:18) or Lampyris noctiluca (SEQ ID NO:20); wherein the amino-acid corresponding to amino acid residue number 245 or 318 in Photinus pyralis luciferase has been substituted with respect to the corresponding wild-type amino acid residue such that the K_(m) for ATP is increased with respect to that of the corresponding non-mutated enzyme.
 2. A recombinant mutant luciferase according to claim 1 wherein the amino-acid corresponding to amino acid residue number 245 in Photinus pyralis luciferase has been substituted with respect to the corresponding wild-type amino acid residue.
 3. A luciferase as claimed in claim 1 wherein the K_(m) is at least double that of the non-mutated enzyme.
 4. A luciferase as claimed in claim 3 wherein the K_(m) is at least five times higher than that of the non-mutated enzyme.
 5. A luciferase as claimed in claim 1 wherein the K_(m) is of the order of 500 μm.
 6. A luciferase as claimed in claim 1 wherein the K_(m) is of the order of 1 mM.
 7. A luciferase as claimed in claim 1 having a V_(m) for ATP which is 5-100% of that of the corresponding wild-type.
 8. A luciferase as claimed in claim 2 wherein the said amino-acid has been substituted for an uncharged amino acid.
 9. A luciferase as claimed in claim 7 wherein the amino-acid has been substituted for Ala, Asn, or Gln.
 10. A luciferase as claimed in claim 1 which is derived from Photinus pyralis and wherein amino acid residue number 245 has, been substituted.
 11. A luciferase as claimed in claim 1 which is derived from Luciola cruciata and wherein amino acid residue number 247 has been substituted.
 12. A luciferase as claimed in claim 1 that includes one or more mutations capable of conferring one or more of the following properties with respect to a corresponding non-mutated enzyme: improved thermostability; or, altered wavelength of emitted light.
 13. A fusion protein comprising a luciferase as claimed in claim
 1. 14. A recombinant polynucleotide encoding a luciferase as claimed in claim
 1. 15. A replication vector comprising a polynucleotide as claimed in claim 14 further comprising a replication element which permits replication of the vector in a suitable host cell.
 16. An expression vector comprising a polynucleotide as claimed in claim 14 further comprising a promoter element which permits expression of said polynucleotide in a suitable host cell.
 17. A vector as claimed in claim 16 wherein the promoter element is tissue or organ specific.
 18. A host cell containing a vector as claimed in claim
 15. 19. A host cell transformed with a vector as claimed in claim
 15. 20. A host cell as claimed in claim 19 which also expresses a second luciferase having a lower K_(m) for ATP.
 21. A host cell as claimed in claim 20 wherein the second luciferase is selected from: (a) a recombinant non-mutant luciferase: and (b) a recombinant mutant luciferase having a mutation which is such that the K_(m) for ATP of the luciferase is decreased with respect to that of the corresponding non-mutated enzyme.
 22. A process for producing a luciferase comprising culturing a host cell as claimed in claim
 19. 23. A method of assaying the amount of ATP in a material, said method comprising the steps of (a) contacting a recombinant mutant luciferase of claim 1 with the material and luciferin; (b) measuring the intensity of light emitted by the luciferase; and (c) the measurement in step (b) is correlated directly with the amount of ATP in the material.
 24. A method according to claim 23 wherein the concentration of the ATP in the material is expected to be between 300 μm and 6 mM.
 25. A method according to claim 23 wherein step (c) is effected by comparison of the measurement obtained in step (b) with a control value.
 26. A method as claimed in claim 23 wherein the measurement in step (b) is monitored continuously.
 27. A method as claimed in claim 23 wherein the material measured is a cell which forms part of a synapse.
 28. A method as claimed in claim 23 wherein the material is a cell and the luciferase is introduced into the cell.
 29. A method as claimed in claim 28 wherein the luciferin is introduced into the cell by direct injection.
 30. A method as claimed in claim 28 wherein the luciferase is introduced into the cell by transforming the cell with a vector comprising a polynucleotide which encodes a recombinant mutant luciferase.
 31. A method of producing a mutant luciferase with an increased Michaelis-Menten constant (K_(m)) for the substrate ATP of a luciferase enzyme having 70% or more homology to luciferase of Photinus pyralis (SEQ ID NO: 21), Luciola cruciata (SEQ ID NO:14), Luciola lateralis (SEQ ID NO:16), Luciola mingrelica (SEQ ID NO:18) or Lampyris noctiluca (SEQ ID NO:20); said method comprising mutating an amino acid residue of said luciferase corresponding to residue 245 or 318 of Photinus pyralis luciferase.
 32. A luciferase produced by the method of claim
 31. 33. In a luciferase having 70% or more homology to luciferase of Photinus pyralis (SEQ ID NO: 21), Luciola cruciata (SEQ ID NO:14), Luciola lateralis (SEQ ID NO:16), Luciola mingrelica (SEQ ID NO:18) or Lampyris noctiluca (SEQ ID NO:20); the improvement comprising a mutated amino acid at the amino acid residue corresponding to residue 245 or 318 of Photinus pyralis luciferase, wherein said improved luciferase has a K_(m) for the substrate ATP which is higher than that of the wild type luciferase.
 34. A test kit comprising a luciferase as claimed in claim 1 and further comprising one or more of the following (a) a buffer or dry materials for preparing a buffer; (b) two or more measured portions of ATP suitable for preparing standard solutions; (c) luciferin; (d) instructions for carrying out an ATP assay. 